>
Switch to:

Fate Therapeutics Return-on-Tangible-Equity

: -28.60% (As of Jun. 2021)
View and export this data going back to 2013. Start your Free Trial

Return-on-Tangible-Equity is calculated as Net Income attributable to Common Stockholders divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Fate Therapeutics's annualized net income attributable to common stockholders for the quarter that ended in Jun. 2021 was $-220.53 Mil. Fate Therapeutics's average shareholder tangible equity for the quarter that ended in Jun. 2021 was $771.08 Mil. Therefore, Fate Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2021 was -28.60%.

The historical rank and industry rank for Fate Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:

NAS:FATE' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -90.37   Med: -57.14   Max: -37.52
Current: -37.52

-90.37
-37.52

During the past 10 years, Fate Therapeutics's highest Return-on-Tangible-Equity was -37.52%. The lowest was -90.37%. And the median was -57.14%.

NAS:FATE's Return-on-Tangible-Equity is ranked lower than
99.99% of the 256 Companies
in the Biotechnology industry.

( Industry Median: -72.87 vs. NAS:FATE: -37.52 )

Fate Therapeutics Return-on-Tangible-Equity Historical Data

The historical data trend for Fate Therapeutics's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fate Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Return-on-Tangible-Equity
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -60.19 -57.14 -56.05 -48.44 -55.11

Fate Therapeutics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Return-on-Tangible-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.39 -52.25 -52.53 -30.71 -28.60

Competitive Comparison

For the Biotechnology subindustry, Fate Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Fate Therapeutics Return-on-Tangible-Equity Distribution

For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Fate Therapeutics's Return-on-Tangible-Equity falls into.



Fate Therapeutics Return-on-Tangible-Equity Calculation

Fate Therapeutics's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2020 is calculated as

Return-on-Tangible-Equity=Net Income attributable to Common Stockholders/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2020 )  (A: Dec. 2019 )(A: Dec. 2020 )
=Net Income attributable to Common Stockholders/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2020 )  (A: Dec. 2019 )(A: Dec. 2020 )
=-173.387/( (244.756+384.445 )/ 2 )
=-173.387/314.6005
=-55.11 %

Fate Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2021 is calculated as

Return-on-Tangible-Equity=Net Income attributable to Common Stockholders/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2021 )  (Q: Mar. 2021 )(Q: Jun. 2021 )
=Net Income attributable to Common Stockholders/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2021 )  (Q: Mar. 2021 )(Q: Jun. 2021 )
=-220.532/( (790.095+752.071)/ 2 )
=-220.532/771.083
=-28.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income attributable to common stockholders of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income attributable to common stockholders data used here is four times the quarterly (Jun. 2021) net income attributable to common stockholders data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Fate Therapeutics  (NAS:FATE) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net income attributable to common stockholders is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Fate Therapeutics Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Fate Therapeutics's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Fate Therapeutics Business Description

Fate Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2836
Traded in Other Exchanges
Address
3535 General Atomics Court, Suite 200, San Diego, CA, USA, 92121
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Executives
Tahl Cindy officer: General Counsel and Secretary C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, STE 200 SAN DIEGO CA 92121
Shoemaker Daniel D officer: Chief Scientific Officer C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, SUITE 200 SAN DIEGO CA 92121
Valamehr Bahram officer: Chief Development Officer C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, STE 200 SAN DIEGO CA 92121
Dulac Edward J Iii officer: Chief Financial Officer FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT STE 200 SAN DIEGO CA 92121
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE BUILDING D, SUITE D3-300 SAN FRANCISCO CA 94129
Green Jeremy director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D SUITE D3-300 SAN FRANCISCO CA 94129
Jooss Karin director C/O GRITSTONE ONCOLOGY, INC. 5858 HORTON STREET, SUITE 210 EMERYVILLE CA 94608
Agarwal Shefali director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Mendlein John director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: MENDLEIN JOHN a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Rastetter William H director 9885 TOWNE CENTRE DR. SAN DIEGO CA 92121
Hershberg Robert director 3005 FIRST AVENUE SEATTLE WA 98121
Coughlin Timothy director 339 NORTH GRANADOS AVE SOLANA BEACH CA 92075
Lee Michael Stewart director C/O REDMILE GROUP, LLC ONE LETTERMAN DR., BLDG. D, SUITE D3-300 SAN FRANCISCO CA 94129
Epstein Robert S director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: EPSTEIN ROBERT S a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Wolchko J Scott director, officer: President and CEO C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, SUITE 200 SAN DIEGO CA 92121

Fate Therapeutics Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)